STAT

As pregnancy tech proliferates, women and their doctors wade through what’s helpful — and what’s a headache

As pregnancy tech proliferates, women and their doctors are wading through what’s helpful — and what’s a headache.

SAN FRANCISCO — Pregnancy care is poised for a 21st century upgrade.

Algorithms promise to detect the difference between real labor and a false alarm. Wearables give women a way to track contractions. Apps relay home blood pressure readings directly to doctors, offering a possible way to cut down on prenatal visits — and catch certain pregnancy complications before they become full-blown crises.

Doctors say the new technologies have the potential to transform prenatal care. But for all the promise, doctors caution that some direct-to-consumer devices might cause anxiety or unnecessary trips to the clinic — without strong evidence that they offer any real benefits to pregnant women.

“Prenatal care is burdensome. It requires patients to be in at minimum, once a month. People have jobs. It’s hard to get in… You could imagine some kind of virtual substitute would be very welcome,” said Dr. Thomas McElrath, an obstetrician-gynecologist at Brigham and Women’s Hospital in Boston. “But we would have to figure out and think carefully about how to do that,” he added.

Obstetrician-gynecologists are particularly worried about direct-to-consumer devices that aren’t woven into the fabric of prenatal care. Among their concerns: Faulty or confusing data might send women to their doctors when they don’t need to go. And for some devices, doctors say the lack of research or a true need to use them means they’re simply a waste of money.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT1 min read
STAT+: In Large Trial, Guardant Health’s Blood Test Detects Colon Cancer, But Less Reliably At Earliest Or Precancerous Stages
If approved, Guardant Health’s liquid biopsy is likely to be a strong new addition to colorectal cancer screening tools, particularly for patients who currently choose not to get screened.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks